# Healthcare & Pharmaceuticals Industry news releases

Healthcare & Pharmaceuticals Industry press releases distributed through Connectively Wire to the journalists who cover the beat.

- **Releases in the last 90 days:** 271
- **Web page:** https://www.connectively.us/news-releases/healthcare-and-pharmaceuticals-industry
- **RSS:** https://www.connectively.us/news-releases/healthcare-and-pharmaceuticals-industry/rss.xml

### [Chronic Care Management Cuts Health Care Costs 13.6% and Patient Out-of-Pocket Costs 16%, Peer-Reviewed Study Finds](https://www.connectively.us/news-releases/chronic-care-management-cuts-health-care-costs-136percent-and-patient)

November 20, 2026 · C3 Health · Healthcare & Pharmaceuticals Industry · MORRISVILLE, NC, UNITED STATES

C3 Health, a leading provider of technology-enabled chronic care management services, today announced the publication of a new Peer-reviewed study by the respected PLOS One organization demonstrating that Medicare beneficiaries participating in Chronic Care Management (CCM)…

### [MagView to Deliver Tracking, Risk Assessment, and Reporting to the Veterans Health Administration With a Phased Rollout](https://www.connectively.us/news-releases/magview-to-deliver-tracking-risk-assessment-and-reporting-to-the)

November 20, 2026 · MagView · Healthcare & Pharmaceuticals Industry · FULTON, MD, UNITED STATES

MagView, whose breast health software is used by more than 2,600 facilities, today announced it has been awarded a contract by the U.S. Department of Veterans Affairs (VA) to provide MagView One as the enterprise mammography tracking and reporting system for the Veterans Health…

### [Life Seal Vascular Reports First-in-Human Results for the Cygnum™ Aneurysm Sac Management Device at VEITHsymposium 2026](https://www.connectively.us/news-releases/life-seal-vascular-reports-first-in-human-results-for-the-cygnumtm)

November 18, 2026 · Life Seal Vascular · Healthcare & Pharmaceuticals Industry · IRVINE, CA, UNITED STATES

Life Seal Vascular, Inc., a clinical-stage medical device company that has developed the Cygnum™ Aneurysm Sac Management Device (ASMD) for patients undergoing endovascular aneurysm repair (EVAR), today announced 30-day safety and six-month efficacy results from the…

### [Lecturio and DEG Impulse Launch AidUP Syria, Building on Measurable Results in Ukraine](https://www.connectively.us/news-releases/lecturio-and-deg-impulse-launch-aidup-syria-building-on-measurable)

November 17, 2026 · Lecturio · Healthcare & Pharmaceuticals Industry · LEIPZIG, GERMANY

Lecturio and DEG Impulse, a subsidiary of Germany’s development finance institution DEG, are expanding AidUP, the disaster medicine education initiative created by Lecturio, to Syria.

### [PRESIDENT SAMIA TO SPEARHEAD AFRICAN DRIVE TO EXPAND SPECIALISED NEWBORN CARE](https://www.connectively.us/news-releases/president-samia-to-spearhead-african-drive-to-expand-specialised)

November 13, 2026 · Secretariet for AU Champion RMNCH · Healthcare & Pharmaceuticals Industry · MWANZA, TANZANIA

Tanzania’s President, Dr. Samia Suluhu Hassan, is launching a continental initiative to expand standard newborn healthcare across Africa. Drawing directly on Tanzania’s domestic success in improving survival rates for premature babies, the program will fund the construction of…

### [Drummond Supports MITRE in Advancing Nationwide Payer API Testing](https://www.connectively.us/news-releases/drummond-supports-mitre-in-advancing-nationwide-payer-api-testing)

November 11, 2026 · Drummond Group, LLC · Healthcare & Pharmaceuticals Industry · DURHAM, NC, UNITED STATES

The U.S. Health and Human Services, Office of the National Coordinator for Health Information Technology (ONC) and Centers for Medicare & Medicaid Services (CMS) have launched a joint initiative to expand collaborative electronic prior authorization (ePA) testing nationwide,…

### [Novaspira Biotherapeutics Reports Phase 1 Data for a Novel GPC3x4-1BB Bispecific in Late-Breaking Oral at SITC 2026](https://www.connectively.us/news-releases/novaspira-biotherapeutics-reports-phase-1-data-for-a-novel-gpc3x4-1bb-2)

November 7, 2026 · Novaspira Biotherapeutics · Healthcare & Pharmaceuticals Industry · CHATHAM, NJ, UNITED STATES

Chatham, NJ, November 7, 2026: Novaspira Biotherapeutics today announced the presentation of first-in-human clinical data for BOS-342 (NS-342), a novel GPC3 × 4-1BB bispecific immunotherapy, in patients with advanced hepatocellular carcinoma (HCC).
